## Sung Joon Hong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2331708/publications.pdf

Version: 2024-02-01

172457 233421 3,177 171 29 45 citations h-index g-index papers 172 172 172 4462 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Postoperative biochemical recurrence of pathologically localized high-grade prostate cancer in adjuvant treatment-na $ ilde{A}$ -ve patients. Journal of Cancer Research and Clinical Oncology, 2020, 146, 221-227.	2.5	1
2	Establishment of patient-derived three-dimensional organoid culture in renal cell carcinoma. Investigative and Clinical Urology, 2020, 61, 216.	2.0	15
3	Long short-term memory artificial neural network model for prediction of prostate cancer survival outcomes according to initial treatment strategy: development of an online decision-making support system. World Journal of Urology, 2020, 38, 2469-2476.	2.2	22
4	Association Between Prostate Cancer and 25-Hydroxyvitamin D2 Levels: National Health and Nutrition Examination Survey 2007â^2008 Results. The Korean Journal of Urological Oncology, 2020, 18, 32-39.	0.1	0
5	Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy. Yonsei Medical Journal, 2020, 61, 652.	2.2	O
6	Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer. Scientific Reports, 2019, 9, 11899.	3.3	2
7	Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio. World Journal of Urology, 2019, 37, 2375-2384.	2.2	10
8	Pathological Characteristics of Prostate Cancer in Men Aged < 50 Years Treated with Radical Prostatectomy: a Multi-Centre Study in Korea. Journal of Korean Medical Science, 2019, 34, e78.	2.5	4
9	Impact of Cerebrovascular Disease on Survival Benefits from Local Treatment in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer. Yonsei Medical Journal, 2019, 60, 1129.	2.2	1
10	The Association of A Number of Predictive Factors for The Recurrence of Papillary Urothelial Neoplasm of Low Malignant Potential: Prognostic Analysis From Multiple Academic Centers. Urology Journal, 2019, 16, 558-562.	0.4	1
11	Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer. Journal of Urology, 2018, 200, 114-120.	0.4	32
12	Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis. BMC Cancer, 2018, 18, 468.	2.6	12
13	Does robotâ€assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases?. BJU International, 2018, 121, 225-231.	2.5	54
14	Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy. Journal of Korean Medical Science, 2018, 33, e285.	2.5	5
15	Tubular organotypic culture model of human kidney. PLoS ONE, 2018, 13, e0206447.	2.5	19
16	Prognostic Factors of Penile Cancer and the Efficacy of Adjuvant Treatment after Penectomy: Results from a Multi-institution Study. Journal of Korean Medical Science, 2018, 33, e233.	2.5	7
17	Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy. Yonsei Medical Journal, 2018, 59, 219.	2.2	3
18	Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis. Yonsei Medical Journal, 2018, 59, 580.	2.2	9

#	Article	IF	CITATIONS
19	Predictors of adverse pathologic features after radical prostatectomy in low-risk prostate cancer. BMC Cancer, 2018, 18, 545.	2.6	11
20	Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients. PLoS ONE, 2018, 13, e0199365.	2.5	16
21	Clinical validation of serum endocan (ESM-1) as a potential biomarker in patients with renal cell carcinoma. Oncotarget, 2018, 9, 662-667.	1.8	13
22	Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses. Cancer Research and Treatment, 2018, 50, 129-137.	3.0	15
23	Diffusionâ€weighted imaging predicts upgrading of Gleason score in biopsyâ€proven low grade prostate cancers. BJU International, 2017, 119, 57-66.	2.5	20
24	Indications for a second prostate biopsy in patients suspected with prostate cancer after an initial negative prostate biopsy. Prostate International, 2017, 5, 24-28.	2.3	2
25	PI-RADS version 2: Preoperative role in the detection of normal-sized pelvic lymph node metastasis in prostate cancer. European Journal of Radiology, 2017, 91, 22-28.	2.6	12
26	Prognostic Significance of Vas Deferens Invasion After Radical Prostatectomy in Patients with Pathological Stage T3b Prostate Cancer. Annals of Surgical Oncology, 2017, 24, 1143-1149.	1.5	7
27	PI-RADS version 2: quantitative analysis aids reliable interpretation of diffusion-weighted imaging for prostate cancer. European Radiology, 2017, 27, 2776-2783.	4.5	19
28	TNF-α-induced Inflammation Stimulates Apolipoprotein-A4 via Activation of TNFR2 and NF-κB Signaling in Kidney Tubular Cells. Scientific Reports, 2017, 7, 8856.	3.3	15
29	Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents. Oncotarget, 2017, 8, 78825-78837.	1.8	6
30	Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study. Yonsei Medical Journal, 2016, 57, 855.	2.2	14
31	Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?. PLoS ONE, 2016, 11, e0147191.	2,5	50
32	Oncological outcomes after partial vs radical nephrectomy in renal cell carcinomas of â‰ቑ cm with presumed renal sinus fat invasion on preoperative imaging. BJU International, 2016, 117, 87-93.	2.5	17
33	Diagnostic impact of dysmorphic red blood cells on evaluating microscopic hematuria: the urologist's perspective. International Urology and Nephrology, 2016, 48, 1021-1027.	1.4	9
34	Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach. Journal of Cancer Research and Clinical Oncology, 2016, 142, 849-858.	2.5	19
35	Prostate Cancer: PI-RADS Version 2 Helps Preoperatively Predict Clinically Significant Cancers. Radiology, 2016, 280, 108-116.	7.3	128
36	Comprehensive analysis and validation of contemporary survival prognosticators in Korean patients with metastatic renal cell carcinoma treated with targeted therapy: prognostic impact of pretreatment neutrophil-to-lymphocyte ratio. International Urology and Nephrology, 2016, 48, 985-992.	1.4	10

#	Article	IF	CITATIONS
37	Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results. European Radiology, 2016, 26, 2502-2509.	4.5	47
38	Effect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical Prostatectomy. PLoS ONE, 2016, 11, e0164497.	2.5	6
39	<i>FOXC2</i> and <i>CLIP4: a potential biomarker for</i> synchronous metastasis of â‰ಢ-cm clear cell renal cell carcinomas. Oncotarget, 2016, 7, 51423-51434.	1.8	26
40	Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma. Neoplasia, 2015, 17, 805-816.	<b>5.</b> 3	17
41	Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP). BMC Cancer, 2015, 15, 812.	2.6	7
42	Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer. Yonsei Medical Journal, 2015, 56, 368.	2.2	3
43	Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer. Yonsei Medical Journal, 2015, 56, 1206.	2.2	28
44	Comparison of computed tomography findings between renal oncocytomas and chromophobe renal cell carcinomas. Korean Journal of Urology, 2015, 56, 695.	1.2	22
45	Repeat Targeted Prostate Biopsy under Guidance of Multiparametric MRI-Correlated Real-Time Contrast-Enhanced Ultrasound for Patients with Previous Negative Biopsy and Elevated Prostate-Specific Antigen: A Prospective Study. PLoS ONE, 2015, 10, e0130671.	2.5	2
46	Adjuvant Radiotherapy Outcome of Stage I Testicular Seminoma: A Single Institution Study. Yonsei Medical Journal, 2015, 56, 24.	2.2	2
47	Prognostic Impact of Time to Undetectable Prostate-Specific Antigen in Patients with Positive Surgical Margins Following Radical Prostatectomy. Annals of Surgical Oncology, 2015, 22, 693-700.	1.5	13
48	Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance. Japanese Journal of Clinical Oncology, 2015, 45, 785-790.	1.3	4
49	Prognostic Impact of Synchronous Second Primary Malignancies on the Overall Survival of Patients with Metastatic Prostate Cancer. Journal of Urology, 2015, 193, 1239-1244.	0.4	7
50	Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2015, 14, 1024-1034.	4.1	27
51	Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels. Prostate International, 2015, 3, 10-15.	2.3	39
52	The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells. BMC Cancer, 2015, 15, 19.	2.6	11
53	Early Application of Permanent Metallic Mesh Stent in Substitution for Temporary Polymeric Ureteral Stent Reduces Unnecessary Ureteral Procedures in Patients With Malignant Ureteral Obstruction. Urology, 2015, 86, 459-464.	1.0	14
54	The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 383.e17-383.e22.	1.6	6

#	Article	IF	CITATIONS
55	Additional Targeted Biopsy in Clinically Suspected Prostate Cancer: Prospective Randomized Comparison between Contrast-Enhanced Ultrasound and Sonoelastography Guidance. Ultrasound in Medicine and Biology, 2015, 41, 2836-2841.	1.5	13
56	Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF21± pathway. Oncotarget, 2015, 6, 34818-34830.	1.8	17
57	Unrecognized Kinetics of Serum Testosterone: Impact on Short-Term Androgen Deprivation Therapy for Prostate Cancer. Yonsei Medical Journal, 2014, 55, 570.	2.2	4
58	Analgesic Opioid Dose Is an Important Indicator of Postoperative Ileus Following Radical Cystectomy with Ileal Conduit: Experience in the Robotic Surgery Era. Yonsei Medical Journal, 2014, 55, 1359.	2.2	21
59	Charlson Comorbidity Index Is an Important Prognostic Factor for Long-Term Survival Outcomes in Korean Men with Prostate Cancer after Radical Prostatectomy. Yonsei Medical Journal, 2014, 55, 316.	2.2	22
60	Clinical Experiences of Incidental Prostate Cancer after Transurethral Resection of Prostate (TURP) According to Initial Treatment: A Study of a Korean High Volume Center. Yonsei Medical Journal, 2014, 55, 78.	2.2	12
61	Treatment outcome of localized prostate cancer by 70 Gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon. Radiation Oncology Journal, 2014, 32, 187.	1.5	17
62	Meta-Analysis of the Relationship between CXCR4 Expression and Metastasis in Prostate Cancer. World Journal of Men?s Health, 2014, 32, 167.	3.3	23
63	Simultaneous Robot-Assisted Laparoendoscopic Single-Site Partial Nephrectomy and Standard Radical Prostatectomy. Yonsei Medical Journal, 2014, 55, 535.	2.2	14
64	Effects of Chemical Castration on Sex Offenders in Relation to the Kinetics of Serum Testosterone Recovery: Implications for Dosing Schedule. Journal of Sexual Medicine, 2014, 11, 1316-1324.	0.6	20
65	Laparoendoscopic singleâ€site ( <scp>LESS</scp> ) robotâ€ssisted nephroureterectomy: comparison with conventional multiport technique in the management of upper urinary tract urothelial carcinoma.  BJU International, 2014, 114, 90-97.	2.5	14
66	Abiraterone acetate and prednisolone for metastatic castrationâ€resistant prostate cancer failing androgen deprivation and docetaxelâ€based chemotherapy: A phase <scp>II</scp> bridging study in <scp>K</scp> orean and <scp>T</scp> aiwanese patients. International Journal of Urology, 2014, 21, 1239-1244.	1.0	11
67	Yonsei nomogram to predict lymph node invasion in <scp>A</scp> sian men with prostate cancer during robotic era. BJU International, 2014, 113, 598-604.	2.5	11
68	Prognostic Factors for Urachal Cancer: A Bayesian Model-Averaging Approach. Korean Journal of Urology, 2014, 55, 574.	1.2	24
69	Impact of Charlson Comorbidity Index Varies by Age in Patients with Prostate Cancer Treated by Radical Prostatectomy: A Competing Risk Regression Analysis. Annals of Surgical Oncology, 2014, 21, 677-683.	1.5	13
70	Low body mass index is associated with adverse oncological outcomes following radical prostatectomy in Korean prostate cancer patients. International Urology and Nephrology, 2014, 46, 1935-1940.	1.4	9
71	Retziusâ€sparing robotâ€assisted laparoscopic radical prostatectomy: combining the best of retropubic and perineal approaches. BJU International, 2014, 114, 236-244.	2.5	121
72	Robotâ€assisted radical prostatectomy in the <scp>K</scp> orean population: A 5â€year propensityâ€score matched comparative analysis versus open radical prostatectomy. International Journal of Urology, 2014, 21, 781-785.	1.0	15

#	Article	IF	CITATIONS
73	Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1769-1776.	2.5	18
74	Prevalence and Management of Lower Urinary Tract Symptoms in Methamphetamine Abusers: An Under-Recognized Clinical Identity. Journal of Urology, 2014, 191, 722-726.	0.4	2
75	Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring. Prostate International, 2014, 2, 76-81.	2.3	4
76	Feasibility of robot-assisted radical prostatectomy for very-high risk prostate cancer: surgical and oncological outcomes in men aged ≥70 years. Prostate International, 2014, 2, 127-132.	2.3	21
77	Extended lymph node dissection in robot-assisted radical prostatectomy: lymph node yield and distribution of metastases. Asian Journal of Andrology, 2014, 16, 824.	1.6	10
78	Tumor Lesion Diameter on Diffusion Weighted Magnetic Resonance Imaging Could Help Predict Insignificant Prostate Cancer in Patients Eligible for Active Surveillance: Preliminary Analysis. Journal of Urology, 2013, 190, 1213-1217.	0.4	50
79	Tumor Volume Adds Prognostic Value in Patients with Organ-Confined Prostate Cancer. Annals of Surgical Oncology, 2013, 20, 3133-3139.	1.5	18
80	Treatment outcomes of chemical castration on Korean sex offenders. Journal of Clinical Forensic and Legal Medicine, 2013, 20, 563-566.	1.0	19
81	Gleason 5+4 Has Worse Oncological and Pathological Outcomes Compared with Gleason 4+5: Significance of Gleason 5 Pattern. Annals of Surgical Oncology, 2013, 20, 3127-3132.	1.5	21
82	Yonsei Criteria: A New Protocol for Active Surveillance in the Era of Robotic and Local Ablative Surgeries. Clinical Genitourinary Cancer, 2013, 11, 501-507.	1.9	8
83	Intermediate-Term Outcomes of Robot-Assisted Laparoscopic Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2013, 11, 515-521.	1.9	28
84	Low-risk Prostate Cancer Patients Without Visible Tumor (T1c) On Multiparametric MRI Could Qualify for Active Surveillance Candidate Even If They Did Not Meet Inclusion Criteria of Active Surveillance Protocol. Japanese Journal of Clinical Oncology, 2013, 43, 553-558.	1.3	27
85	Upgrading of <scp>G</scp> leason score and prostate volume: a clinicopathological analysis. BJU International, 2013, 111, 1310-1316.	2.5	24
86	Extended vs standard lymph node dissection in robotâ€assisted radical prostatectomy for intermediate― or highâ€risk prostate cancer: a propensityâ€scoreâ€matching analysis. BJU International, 2013, 112, 216-223.	2.5	41
87	Inhibition of tumor growth and histopathological changes following treatment with a chemokine receptor CXCR4 antagonist in a prostate cancer xenograft model. Oncology Letters, 2013, 6, 933-938.	1.8	20
88	Biochemical outcomes after robot-assisted radical prostatectomy in patients with follow-up more than 5-years. Asian Journal of Andrology, 2013, 15, 404-408.	1.6	9
89	Reduction of the CD16â^CD56bright NK Cell Subset Precedes NK Cell Dysfunction in Prostate Cancer. PLoS ONE, 2013, 8, e78049.	2.5	59
90	Inhibition of IGF-1 Signaling by Genistein: Modulation of E-Cadherin Expression and Downregulation of $\hat{l}^2$ -Catenin Signaling in Hormone Refractory PC-3 Prostate Cancer Cells. Nutrition and Cancer, 2012, 64, 153-162.	2.0	54

#	Article	IF	Citations
91	Extended Pelvic Lymph Node Dissection Including Internal Iliac Packet Should Be Performed During Robot-Assisted Laparoscopic Radical Prostatectomy for High-Risk Prostate Cancer. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2012, 22, 785-790.	1.0	44
92	Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia. BJU International, 2012, 109, 88-95.	2.5	92
93	Sorafenib treatment of Asian patients with advanced renal cell carcinoma (RCC) in daily practice: Subset analysis of the large non-interventional PREDICT study Journal of Clinical Oncology, 2012, 30, 4628-4628.	1.6	2
94	Immediate robot-assisted ureteral reimplantation during robotic prostatectomy in locally advanced prostate cancer. Journal of Robotic Surgery, 2011, 5, 149-151.	1.8	0
95	lliac Vein Injury Due to a Damaged Hot Shearsâ,,¢ Tip Cover During Robot Assisted Radical Prostatectomy. Yonsei Medical Journal, 2011, 52, 365.	2.2	10
96	Robotâ€assisted laparoscopic radical prostatectomy in the Asian population: Modified port configuration and ultradissection. International Journal of Urology, 2010, 17, 297-300.	1.0	22
97	Trends in the incidence of benign pathological lesions at partial nephrectomy for presumed renal cell carcinoma in renal masses on preoperative computed tomography imaging: A single institute experience with 290 consecutive patients. International Journal of Urology, 2010, 17, 512-516.	1.0	17
98	Warm Sitz Bath: Are There Benefits after Transurethral Resection of the Prostate?. Korean Journal of Urology, 2010, 51, 763.	1,2	6
99	High-Grade Hydronephrosis Predicts Poor Outcomes After Radical Cystectomy in Patients with Bladder Cancer. Journal of Korean Medical Science, 2010, 25, 369.	2.5	21
100	Pattern of Failure in Bladder Cancer Patients Treated with Radical Cystectomy: Rationale for Adjuvant Radiotherapy. Journal of Korean Medical Science, 2010, 25, 835.	2.5	4
101	The Urologist's View of Male Overactive Bladder: Discrepancy between Reality and Belief in Practical Setting. Yonsei Medical Journal, 2010, 51, 432.	2.2	6
102	Efficacy of Adjuvant Gemcitabine-Cisplatin Chemotherapy: A Comparative Study between Locally Advanced Transitional Cell Carcinoma of the Bladder and Upper Urinary Tract. Urologia Internationalis, 2010, 85, 47-51.	1.3	8
103	Relationship between Prostate-Specific Antigen and Body Mass Index according to Age: Lower Prostate-Specific Antigen in Middle-Aged Overweight and Obese Korean Men. Urologia Internationalis, 2010, 85, 143-146.	1.3	2
104	Lipid raft cholesterol and genistein inhibit the cell viability of prostate cancer cells via the partial contribution of EGFR-Akt/p70S6k pathway and down-regulation of androgen receptor. Biochemical and Biophysical Research Communications, 2010, 393, 319-324.	2.1	42
105	Lymphovascular Invasion and pT Stage Are Prognostic Factors in Patients Treated with Radical Nephroureterectomy for Localized Upper Urinary Tract Transitional Cell Carcinoma. Urology, 2010, 75, 328-332.	1.0	56
106	Assessment of Patient-Reported Outcome of Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Tamsulosin HCl in Korea. Urology, 2010, 75, 1156-1161.	1.0	12
107	Preventive Effects of Oligomerized Polyphenol on Estradiol-Induced Prostatitis in Rats. Yonsei Medical Journal, 2009, 50, 391.	2.2	17
108	Management of BCG Failures in Non-Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2009, 50, 1037.	1.2	3

#	Article	IF	Citations
109	Clinical Significance of Lymph Node Dissection in Patients with Muscle-Invasive Upper Urinary Tract Transitional Cell Carcinoma Treated with Nephroureterectomy. Journal of Korean Medical Science, 2009, 24, 674.	2.5	15
110	The Risk Factor for Urethral Recurrence after Radical Cystectomy in Patients with Transitional Cell Carcinoma of the Bladder. Urologia Internationalis, 2009, 82, 306-311.	1.3	47
111	The "halo effect―in Korea: change in practice patterns since the introduction of robot-assisted laparoscopic radical prostatectomy. Journal of Robotic Surgery, 2009, 3, 57-60.	1.8	5
112	Failing to achieve a nadir prostateâ€specific antigen after combined androgen blockade: Predictive factors. International Journal of Urology, 2009, 16, 670-675.	1.0	8
113	Malfunction of da Vinci Robotic System—Disassembled Surgeon's Console Hand Piece: Case Report and Review of the Literature. Urology, 2009, 73, 209.e7-209.e8.	1.0	12
114	Differences in Tumor Characteristics and Prognosis in Newly Diagnosed Ta, T1 Urothelial Carcinoma of Bladder According to Patient Age. Urology, 2009, 73, 828-832.e1.	1.0	21
115	Prostate-Specific Antigen Test Interval according to Baseline Prostate-Specific Antigen and Age. Korean Journal of Urology, 2009, 50, 1059.	1.2	0
116	A Multicenter Prospective Study of the Risk Factors Affecting Bone Mineral Density in Korean Patients with Prostate Cancer. Korean Journal of Urology, 2009, 50, 327.	1.2	0
117	The overlooked cause of benign prostatic hyperplasia: prostatic urethral angulation. Medical Hypotheses, 2008, 70, 532-535.	1.5	30
118	Relationship Between Prostatic Urethral Angle and Urinary Flow Rate: Its Implication in Benign Prostatic Hyperplasia Pathogenesis. Urology, 2008, 71, 858-862.	1.0	37
119	Histologic type, staging, and distribution of germ cell tumors in Korean adults. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 590-594.	1.6	6
120	Robot-Assisted Laparoscopic Radical Cystoprostatectomy with Ileal Conduit Urinary Diversion: Initial Experience in Korea. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2008, 18, 401-404.	1.0	6
121	The Prognostic Significance of Pathologic Stage TO on Organ-Confined Bladder Transitional Cell Carcinoma following Radical Cystectomy. Urologia Internationalis, 2008, 81, 394-398.	1.3	8
122	The Relationship between Metabolic Syndrome and Prostate Volume in Men Over Sixties who Underwent Prostate Health Check-up. Korean Journal of Urology, 2008, 49, 813.	0.2	8
123	A Comprehensive Prognostic Stratification for Patients with Metastatic Renal Clear Cell Carcinoma. Yonsei Medical Journal, 2008, 49, 451.	2.2	9
124	Nomograms for Prediction of Disease Recurrence in Patients with Primary Ta, T1 Transitional Cell Carcinoma of the Bladder. Journal of Korean Medical Science, 2008, 23, 428.	2.5	28
125	The Patterns and Risk Factors for Subsequent Bladder Recurrence in Patients with Transitional Cell Carcinoma of the Upper Urinary Tract: A Long-Term Follow-Up Study. Korean Journal of Urology, 2008, 49, 294.	0.2	2
126	Prognostic Impact of Peripelvic Fat Invasion in pT3 Renal Pelvic Transitional Cell Carcinoma. Journal of Korean Medical Science, 2008, 23, 434.	2.5	11

#	Article	IF	Citations
127	A Multi-institutional Study on Histopathological Characteristics of Surgically Treated Renal Tumors: the Importance of Tumor Size. Yonsei Medical Journal, 2008, 49, 639.	2.2	6
128	Lowering Prostate-specific Antigen Threshold for Prostate Biopsy in Korean Men: Impact on the Number Needing Biopsy. Korean Journal of Urology, 2008, 49, 118.	0.2	4
129	Yonsei Experience in Robotic Urologic Surgery - Application in Various Urological Procedures. Yonsei Medical Journal, 2008, 49, 897.	2.2	28
130	Impact of Caveolin-1 Expression on the Prognosis of Transitional Cell Carcinoma of the Upper Urinary Tract. Journal of Korean Medical Science, 2008, 23, 296.	2.5	12
131	CT Findings After Nephron-Sparing Surgery of Renal Tumors. American Journal of Roentgenology, 2007, 189, W264-W271.	2.2	13
132	Grade of Hydronephrosis and Tumor Diameter as Preoperative Prognostic Factors in Ureteral Transitional Cell Carcinoma. Urology, 2007, 70, 662-666.	1.0	73
133	Age-Specific Prostate-Specific Antigen Reference Ranges in Korean Men. Urology, 2007, 70, 1113-1116.	1.0	24
134	A proposal for a novel staging system in renal pelvicaliceal urothelial carcinomas. Human Pathology, 2007, 38, 1639-1648.	2.0	8
135	A Prospective, Multicenter, Open-label Trial of Zoledronic Acid in Patients with Hormone Refractory Prostate Cancer. Yonsei Medical Journal, 2007, 48, 1001.	2.2	4
136	Clinico-pathological Characteristics of Prostate Cancer in Korean Men and Nomograms for the Prediction of the Pathological Stage of the Clinically Localized Prostate Cancer: A Multi-institutional Update. Korean Journal of Urology, 2007, 48, 125.	0.2	12
137	The Difference in the Prognosis and Characteristics between the Progressive and Primary Muscle-invasive Bladder Cancer Treated with Radical Cystectomy. Korean Journal of Urology, 2007, 48, 1109.	0.2	7
138	Predictive Variables of the Progression to Androgen Independent Prostate Cancer after Combined Androgen Blockade. Korean Journal of Urology, 2007, 48, 408.	0.2	5
139	Estramustine Phosphate Based Chemotherapy for Hormone Refractory Prostate Cancer. Korean Journal of Urology, 2007, 48, 684.	0.2	4
140	Identification of Enhancer of Zeste Homolog 2 Expression in Peripheral Circulating Tumor Cells in Metastatic Prostate Cancer Patients: A Preliminary Study. Yonsei Medical Journal, 2007, 48, 1009.	2.2	9
141	Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFRâ€mediated Akt and ERK signal transduction. Prostate, 2007, 67, 1061-1069.	2.3	90
142	Correlation of Cyclooxygenase-2 Expression and Microvessel Density with Prognosis in Transitional Cell Carcinoma of the Upper Urinary Tract. Korean Journal of Urology, 2007, 48, 376.	0.2	0
143	Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: A multicenter study. Urology, 2006, 67, 333-336.	1.0	36
144	Long-term effects of ileal conduit urinary diversion on upper urinary tract in bladder cancer. Urology, 2006, 68, 324-327.	1.0	49

#	Article	IF	CITATIONS
145	Safety and Efficacy of Intravesical Keyhole-Limpet Hemocyanin Therapy for Superficial Transitional Cell Carcinoma: A Prospective, Multicenter Study. Korean Journal of Urology, 2006, 47, 824.	0.2	1
146	The Role of Alpha 1 (A) Adrenoceptor Antagonist Tamsulosin for the Treatment of Patients with Benign Prostatic Hyperplasia: The Effect on Lower Urinary Tract Symptoms and Nocturia. Korean Journal of Urology, 2006, 47, 1.	0.2	15
147	The Effects of GAC on the Biochemical Profiles and Quality of Life of Metastatic Prostate Cancer Patients. Korean Journal of Urology, 2006, 47, 467.	0.2	3
148	Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension. BJU International, 2006, 97, 90-95.	2.5	12
149	Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. BJU International, 2006, 97, 742-746.	2.5	44
150	The Use of Complementary and Alternative Medicine in Patients with a Urological Malignancy. Korean Journal of Urology, 2006, 47, 620.	0.2	5
151	The Effect of Cyclooxygenase-2 Inhibitor on the Gene Expression Profile of N-butyl-N-(4-hydroxybutyl) nitrosamine-induced Rat Urinary Bladder Cancer. Korean Journal of Urology, 2006, 47, 310.	0.2	0
152	Internet Based Multi-institute Prostate Research System: Pilot Experience with a Convenient, Secure and Efficient System. Korean Journal of Urology, 2006, 47, 387.	0.2	0
153	The Influence of Age and Prostate Volume on the Cancer Detection Rate in Korean Men with PSA Levels of 4.0 to 10.0ng/ml: a Multicenter, Retrospective Study. Korean Journal of Urology, 2006, 47, 353.	0.2	2
154	The Effects of Neoadjuvant External Beam Radiotherapy on Pathologic Stage T3 Bladder Transitional Cell Carcinoma. Korean Journal of Urology, 2006, 47, 232.	0.2	0
155	Contralateral Testicular Single Metastasis from Renal Cell Carcinoma. Korean Journal of Urology, 2006, 47, 108.	0.2	1
156	Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Korean Men. Korean Journal of Urology, 2006, 47, 586.	0.2	6
157	The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU International, 2005, 95, 15-19.	2.5	41
158	Antiangiogenic Effect of ZD1839 against Murine Renal Cell Carcinoma (RENCA) in an Orthotopic Mouse Model. Urologia Internationalis, 2005, 75, 159-166.	1.3	8
159	Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice. International Journal of Urology, 2005, 12, 159-165.	1.0	8
160	Percutaneous Sclerotherapy of Renal Cysts with a Beta-Emitting Radionuclide, Holmium-166-chitosan Complex. Korean Journal of Radiology, 2004, 5, 128.	3.4	25
161	A comparative multicentre study on the incidence of catheter-associated urinary tract infection between nitrofurazone-coated and silicone catheters. International Journal of Antimicrobial Agents, 2004, 24, 65-69.	2.5	52
162	Radical Prostatectomy. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2004, 47, 417.	0.1	0

#	Article	IF	CITATIONS
163	Identification of Baseline Clinical Factors Which Predict Medical Treatment Failure of Benign Prostatic Hyperplasia: An Observational Cohort Study. European Urology, 2003, 44, 94-100.	1.9	37
164	Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology, 2002, 60, 816-821.	1.0	58
165	Comparative Study of Concentration of Isoflavones and Lignans in Plasma and Prostatic Tissues of Normal Control and Benign Prostatic Hyperplasia. Yonsei Medical Journal, 2002, 43, 236.	2.2	72
166	The loss of expression of transforming growth factor- $\hat{l}^2$ receptors correlates with the histopathologic tumor grade in bladder transitional cell carcinoma patients. Yonsei Medical Journal, 1999, 40, 118.	2.2	3
167	Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clinical Biochemistry, 1999, 32, 405-409.	1.9	79
168	Telomerase activity: a potential marker of bladder transitional cell carcinoma in bladder washes. Yonsei Medical Journal, 1997, 38, 155.	2.2	14
169	A PCR-RFLP method for the detection of activated H-ras oncogene with a point mutation at codon 12 and 61. Yonsei Medical Journal, 1996, 37, 371.	2.2	9
170	Testosterone productivity and histostructural changes of autotransplanted rat Leydig cells. Yonsei Medical Journal, 1994, 35, 260.	2.2	5
171	Treatment response with transurethral radiofrequency thermotherapy for symptomatic benign prostatic hyperplasia. Yonsei Medical Journal, 1994, 35, 279.	2.2	1